Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma By Ogkologos - December 18, 2024 930 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Los obstáculos en la atención para las personas LGBTQ con cáncer:... January 21, 2021 Over 600 people in England set to benefit from innovative lung... December 1, 2021 Fruquintinib Prolongs Survival Compared with Placebo in Heavily Pretreated Patients with... June 27, 2023 Analysis Patterns of Systemic Anticancer Treatment at End-of-Life Indicates No Changes... November 2, 2022 Load more HOT NEWS Are differences in treatment driving variation in ovarian cancer survival internationally? FDA Approves Rituximab Plus Chemotherapy for Paediatric Cancer Indications FDA Grants Accelerated Approval to Tucatinib with Trastuzumab for Colorectal Cancer Pembrolizumab Demonstrates Robust, Durable Antitumour Activity and Promising Survival in Advanced...
